Date receipt dossier
EudraCT number
2017-002261-22
Company / Sponsor
Kite Pharma
Phase
III
Treated organism
Humans
Indication category
Cancer therapy
Disease
B cell malignancies
Therapeutic approach
Immunotherapy
Genetic modification
Chimeric antigen receptor against CD19
Method of transfer of nucleic acid of interest
Retroviral vectors
Administered biological material
Autologous T cells transduced with retroviral vectors (YESCARTA, Axicabtagene ciloleucel)
Route of administration
Intravenous
Locations in Belgium
UCL (Hôpital Saint-Luc)
Nr of subjects
6
Type of procedure
Contained use only
Current status
Authorized